Recently Featured

Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19

March 8, 2026
Bioxytran, Inc. recently announced promising results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study of oral ProLectin-M in hospitalized patients with mild to moderate COVID-19. The study demonstrated that the highest evaluated dose of ProLectin-M (16,800 mg/day) led to statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared to placebo,…

UniQure’s Huntington’s Disease Therapy Approval Blocked by FDA Amid Regulatory Concerns

March 7, 2026
UniQure announced on Monday that its efforts to secure approval for a Huntington’s disease treatment from the Food and Drug Administration (FDA) remain obstructed, marking another hurdle for a therapy that previously seemed poised for approval. In a recent meeting with the FDA, UniQure learned that regulators remain unconvinced that the data from its completed…

UniQure Faces Setback as FDA Prefers Randomized Trial for Huntington’s Treatment

March 7, 2026
UniQure’s stock experienced a decline on Monday following unfavorable feedback from the FDA regarding its Huntington’s disease program, AMT-130. The agency indicated that the current application lacks sufficient data to support its approval, specifically expressing a preference for a randomized clinical trial to validate the treatment’s efficacy. This development underscores the FDA’s stringent requirements for…

Kennedy adds 2 new members to CDC’s vaccine panel ahead of delayed meeting

March 7, 2026
The Centers for Disease Control and Prevention (CDC) has appointed two new members to its Advisory Committee on Immunization Practices (ACIP) as it prepares for a postponed meeting. The new appointees, Dr. Sean G. Downing, a specialist in internal medicine and pediatrics from Florida, and Dr. Angelina Farella, a pediatrician, bring valuable expertise to the…

Ongoing Cases